Smith & Nephew restructuring provides potential $750 million war chest
This article was originally published in Clinica
Executive Summary
Smith & Nephew, the UK orthopaedics, wound management and endoscopy company, could have as much as £500 million ($750 million) to spend on acquiring new businesses. The company's CEO Chris O'Donnell said that financial restructuring has given S&N a borrowing power that will enable it to add companies at the rate of two or three a year.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.